Luye Pharma Group (HKG:2186) booked 618.7 million yuan in attributable profit for 2025, rising 31% from 471.9 million yuan in 2024, according to a Hong Kong bourse filing Tuesday.
Earnings per share were 0.1250 yuan, compared with 0.1254 yuan in the prior year.
Revenue rose 4.1% year on year to 6.31 billion yuan, figures showed.
The company did not declare a final dividend for the year.
Shares of the company were up nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments